Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-06-14

Schrödinger, Inc.

Schrödinger sells molecular discovery software and workflow tools and also captures downstream value through partnered and selective proprietary drug discovery programs.

ai biotech enterprise healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Workflow proof, not pipeline heroics, drives upside

The upside case is a cleaner discovery operating layer with better software quality and measured partner optionality. The stock can more than double by 2031 if hosted delivery and new AI workflow tools deepen control of discovery programs rather than just add scientific utility.

Analysis

Thesis

Schrödinger can more than double equity value by 2031 if hosted delivery, LiveDesign workflow control, and Bunsen-driven program throughput convert a niche science software stack into a cleaner discovery operating layer with recurring software economics plus partner optionality, without drifting back into balance-sheet-heavy biotech risk.

Last Economy Alignment

Cheaper compute and AI should expand demand for computational discovery, and Schrödinger owns both hard-to-copy science know-how and a shared workflow surface. It benefits from the Last Economy, but it is not immune to large-pharma in-sourcing or agents routing work to cheaper tools.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.2x (from 5 most recent analyses)

Reasoning

The upside is a quality rerating plus sustained compounding, not a heroic drug-pipeline bet. Schrödinger already has real enterprise software, sticky scientific workflows, and partner validation; if hosted contracts mature well and Bunsen expands value per discovery program, investors can revalue it from a noisy niche tool vendor toward a cleaner workflow-and-outcomes platform. I still keep the upside below true platform leaders because pricing durability and AI-era control remain to be proven.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is validation, not survival. Schrödinger must prove that hosted ACV growth, Bunsen usage, and deeper workflow embedding translate into durable revenue quality, better cash generation, and real pricing power before the market will treat it as a discovery operating layer rather than a useful but replaceable scientific tool.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

A June 5, 2026 8-K formalized the separation agreement with the former chief commercial officer, adding a near-term go-to-market execution watch but not changing the core platform thesis.
No material operating disclosure arrived in the last 7-10 days, so the investment case still rests on the May 5, 2026 Q1 update and the pending summer 2026 Bunsen launch window.
The June 22, 2026 annual meeting is now the nearest scheduled catalyst; the proposed 3.0 million share-plan increase matters more for dilution optics and retention flexibility than for business fundamentals.

Thesis update

No core change. Recent filings mainly raise a commercial execution watch rather than alter the platform, TAM, or balance-sheet picture.

Forecast update

Slightly lower because the hosted shift is still depressing recognized software revenue while the new AI layer remains pre-pricing; I want proof before underwriting a cleaner rerating.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.51

They control useful science software and a shared workspace where drug teams coordinate work, so cheaper AI and compute can send more activity through their system. The risk is that big pharma keeps core data control in-house and lets agents call cheaper tools directly, which would weaken pricing power.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$20.88

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research